![Sanofi and Teva Ink Deal Worth Potentially $1.5B for Anti-TL1A IBD Candidate | Inside Precision Medicine Sanofi and Teva Ink Deal Worth Potentially $1.5B for Anti-TL1A IBD Candidate | Inside Precision Medicine](https://www.insideprecisionmedicine.com/wp-content/uploads/2022/08/IBD-1412268592.jpg)
Sanofi and Teva Ink Deal Worth Potentially $1.5B for Anti-TL1A IBD Candidate | Inside Precision Medicine
![Teva Launches 'It's Not OK - It's TD' National Television Advertising Campaign to Increase Awareness of Tardive Dyskinesia and AUSTEDO® (deutetrabenazine) tablets Teva Launches 'It's Not OK - It's TD' National Television Advertising Campaign to Increase Awareness of Tardive Dyskinesia and AUSTEDO® (deutetrabenazine) tablets](https://mma.prnewswire.com/media/1510758/Teva_Logo.jpg?p=facebook)
Teva Launches 'It's Not OK - It's TD' National Television Advertising Campaign to Increase Awareness of Tardive Dyskinesia and AUSTEDO® (deutetrabenazine) tablets
![Two-drug combo helps older adults with hard-to-treat depression - The Source - Washington University in St. Louis Two-drug combo helps older adults with hard-to-treat depression - The Source - Washington University in St. Louis](https://source.wustl.edu/wp-content/uploads/2016/12/antidepressants-700x467-600x400.jpg)